UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

 

Date of Report (Date of earliest event reported):       December 20, 2017

 

 

 

VITRO DIAGNOSTICS, INC.
(Exact Name of Registrant as Specified in its Charter)

 

 

       Nevada       

       0-17378       

    84-1012042    

(State or other jurisdiction
of incorporation)

Commission File
Number

(I.R.S. Employer Identification number)

 

 

4621 Technology Drive, Golden CO  80403
(Address of principal executive offices)                    (Zip Code)

 

Registrant's telephone number, including area code:    (303) 999-2130

 

______________________________________________________

(Former name or former address, if changed since last report)

 

 

___

Written communications pursuant to Rule 425 under the Securities Act

___

Soliciting material pursuant to Rule 14a-12 under the Exchange Act

___

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act

___

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company [ X ]  

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.    [     ]

ITEM 2.02 RESULTS OF OPERATION AND FINANCIAL CONDITION  

ITEM 7.01 REGULATION FD DISCLOSURE  

 

On December 20, 2017, Vitro Diagnostics, Inc. (OTCQB: VODG) (the “Company”) issued a press release announcing its CEO letter to shareholders including discussion of 2016/2017 results and plans for 2018, including regenerative medicine initiatives for expanding indications.  The press release also announces record revenues for 2017 based on both expansion of revenues from its core products, including cancer-associated fibroblasts used to accelerate development of immunotherapy of solid tumors and especially new revenues derived from stem cell therapies.  The financial statements (unaudited) for 2016 and 2017 are included in the press release, a copy of which is filed herewith as Exhibit 99.1.

The information in this Current Report on Form 8-K furnished pursuant to Item 7.01, including Exhibit 99.1, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to liability under that section, and they shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing. By filing this Current Report on Form 8-K and furnishing this information pursuant to Item 7.01, The Company makes no admission as to the materiality of any information in this Current Report on Form 8-K, including Exhibit 99.1, that is required to be disclosed solely by Regulation FD.

 

 

ITEM 9.01 : EXHIBITS  

 

 

Item

Title

 

 

 

 

99.1

Press Release

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

 

Vitro Diagnostics, Inc.
(Registrant)

 

 

 

 

 

Dated:   December 27, 2017

 

__ _/s/ James R. Musick__ ____
James R. Musick, President and CEO

 

 

 

 

2